MARATTO

article · PLoS ONE

Persistent proteinuria among a cohort of Nigerian children with sickle cell anaemia

2026Open accessUniversity of Lagos

Abstract

BACKGROUND: Persistent proteinuria is an early and modifiable marker of kidney damage. Although Nigeria has the highest burden of sickle cell anaemia (SCA) globally, the prevalence of proteinuria is unknown largely because many of the studies only determined proteinuria in a single urine sample or used less sensitive methods, such as dipstick. Unlike dipstick screening, quantitative urine protein-creatinine ratio allows more accurate detection of low-grade proteinuria. OBJECTIVES: To determine the prevalence and determinants of persistent proteinuria among children with SCA. METHODS: Children with SCA and age and sex-matched controls attending a publicly funded hospital in central Nigeria were consecutively enrolled. Proteinuria was determined at the first visit using the spot urine protein creatinine ratio and repeated at least 3 months afterwards for those with proteinuria. In addition, serum creatinine, full blood count, and fetal hemoglobin were determined at the first visit. Persistent proteinuria was defined as a urine protein-to-creatinine ratio ≥0.2 at both visits over a follow-up period of at least 3 months. Participants were classified based on the presence or absence of persistent proteinuria, and baseline characteristics were compared using within-group distributions for categorical variables with appropriate statistical tests. RESULTS: One hundred and forty-nine children, each with SCA and controls, were enrolled, respectively. The median (IQR) age of the study participants was 9.0 (6.0) years for both groups, with 65% being males. Persistent proteinuria occurred in 35 (23.5%) children with SCA versus 4 (2.7%) controls (p-value < 0.01). Children with persistent proteinuria had a lower level of fetal hemoglobin. (adjusted OR 0.583, 95% C.I 0.473-0.719). CONCLUSION: About a quarter of children with SCA had persistent proteinuria, an early and modifiable marker of chronic kidney disease.

Research topics

  • Hemoglobinopathies and Related Disorders
  • Blood groups and transfusion
  • Clinical Laboratory Practices and Quality Control

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1371/journal.pone.0347556

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.